Life Sciences Opportunities in India & China: From Innovation to Commercialization
30 September 2009
China and India are emerging as major players in the life sciences industry. Both countries have a wealth of top talent as well as rapidly-improving resources for the industry. Both countries also constitute important current and potential markets for drugs, devices and diagnostics, and are also projected to be major sources of innovation in the not-too-distant future. This panel will explore the significant opportunities in China and India, in terms not only of expanding operations to both countries, but also in terms of working with innovative companies that originate from China and India.
Moderator:
- David A. Charapp, Special Counsel, Foley & Lardner LLP
Panelists:
- Stephen A. Bent, Partner, Foley & Lardner LLP
- Friedhelm Blobel, Ph.D., President, CEO, Director, SciClone Pharmaceuticals
- Kim Kamdar, Ph.D., Principal at Domain Associates
- Sanjay Shukla, M.D., M.S., Chief Executive Officer, RxMD
Related Insights
08 December 2023
Foley Ignite
An Update on Reauthorizing the National Quantum Initiative
Signed into law in 2018, the goal of the National Quantum Initiative Act was “to accelerate quantum research and development for the economic and national security of the United States.”
08 December 2023
Innovative Technology Insights
FDA Approves Two Gene Therapies to Treat Sickle Cell Disease Including a CRISPR-Based Therapy
These new therapies harness the power of stem cells to help patients with sickle cell disease avoid vaso-oclusive events and crises.
08 December 2023
Foley Ignite
2024 Predictions: Unveiling the future of healthcare mergers and acquisitions
Foley & Lardner's Nathaniel Lacktman and Louis Lehot discuss which categories of digital health hold the most potential for M&As and why.